CAS: 149709-58-0; (R)-α-[[(1,1-Dimethylethoxy)Carbonyl]Amino][1,1'-Biphenyl]-4-Propanal

该化合物是一个化学化合物,其结构复杂,包括一个氨基甲酸酯功能组.该化合物的特性是三丁基酯组(1,1-二甲基乙基),其成份有可能会影响其再活性和溶性.双苯基混合物的存在表明,它可能表现出有趣的电子特性,可能影响其在生物系统或材料科学应用中的相互作用.(1R)配置表明,其体性在确定该化合物的生物活动和药理特性方面可能具有重要意义.一般来说,这种性质的化合物可能用于制药,农业化学品或有机合成的中间体.熔点,沸点,溶性,溶性及稳定性等具体特性需要实证数据,以便精确评估,但结构特征表明,这种化合物在各种化学应用中具有潜在效用.

英文名称(R)-α-[[(1,1-Dimethylethoxy)Carbonyl]Amino][1,1'-Biphenyl]-4-Propanal
中文名称SacubitRil(LCZ696)中间体
CAS编号149709-58-0
MFCD编号:MFCD28359222
FDA UNII编号:46ZSJ34Z8Y
分子式:C20H23NO3
分子量:325.4
产品CID: 722772
产品分类分析化学 → 标准品 → 药典标准品和杂质标准品

相似结构搜索
InChIKey: OWIZSBUSCSIZSA-GOSISDBHSA-N
1S/C20H23NO3/c1-20(2,3)24-19(23)21-18(14-22)13-15-9-11-17(12-10-15)16-7-5-4-6-8-16/h4-12,14,18H,13H2,1-3H3,(H,21,23)/t18-/m1/s1…
计算化学: 氢键受体数3.0氢键供体数1.0可旋转键数7.0

MSDS等安全信息

上下游产品

CAS号149709-59-1 (R,E)-5-((1,1-联...

合成工艺路线路线简述

Methyl N-(Tert-Butoxycarbonyl)-O-[(Trifluoromethyl)Sulfonyl]-D-Tyrosinate置于四(三苯基膦)钯 Sodium Hydroxide,Lithium Aluminium Tetrahydride,Potassium Carbonate,1-羟基苯并三唑,盐酸-N-乙基-N'-(3-二甲氨基丙基)碳二亚胺,三乙胺体系中,用四氢呋喃,甲醇,乙醚,二氯甲烷,甲苯用作溶剂,化学反应 18.33H,反应生成[(1R)-2-(联苯-4-基)-1-甲酰基乙基]氨基甲酸叔丁酯
参考文献:Dicarboxylic Acid Dipeptide Neutral Endopeptidase Inhibitors
标题:Dicarboxylic Acid Dipeptide Neutral Endopeptidase Inhibitors
摘要:The Synthesis Of Three Series Of Dicarboxylic Acid Dipeptide Neutral Endopeptidase 24.11 (Nep) Inhibitors Is Described. In Particular,The Amino Butyramide 21A Exhibited Potent Nep Inhibitory Activity (Ic50 = 5.0 Nm) In Vitro And In Vivo. Blood Levels Of 21A Were Determined Using An Ex Vivo Method By Measuring Plasma Inhibitory Activity In Conscious Rats,Mongrel Dogs,And Cynomolgus Monkeys. Free Drug Concentrations Were 10-1500 Times Greater Than The Inhibitory Constant For Nep Over The Course Of A 6 H Experiment. A Good Correlation Of Free Drug Concentrations Was Obtained When Comparing Values Determined By The Ex Vivo Analysis To Those Calculated From Direct HPLC Measurements. Plasma Atrial Natriuretic Factor (Exogenous) Levels Were Elevated In Rats And Dogs After Oral Administration Of 19A. Urinary Volume And Urinary Sodium Excretion Were Also Potentiated In Anesthetized Dogs Treated With 21A.
Doi:10.1021/jm00010A014